{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:28:55Z","timestamp":1770884935922,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008235","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T00:00:00Z","timestamp":1309910400000}}],"reference-count":49,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008235.pub2","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T20:55:14Z","timestamp":1309812914000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["TPO receptor agonist for chronic idiopathic thrombocytopenic purpura"],"prefix":"10.1002","volume":"2011","author":[{"given":"Yan","family":"Zeng","sequence":"first","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Hematology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Duan","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Orthopaedic Surgery; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Xu","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Mental Health Centre; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Ni","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Hematology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,6]]},"reference":[{"key":"10.1002\/14651858.CD008235.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008235.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ajh.21463","article-title":"Quantifying the reduction in immunoglobulin (Ig) use over time in patients with chronic immune thrombocytopenic purpura (ITP) receiving romiplostim (AMG531)","volume":"84","author":"Pullarkat","year":"2009","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD008235.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ajh.21463","article-title":"Quantifying the reduction in immunoglobulin (Ig) use over time in patients withchronic immune thrombocytopenic purpura (ITP) receiving romiplostim (AMG531)","volume":"84","author":"Pullarkat","year":"2009","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008235.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114(18)","author":"Kuter","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0014|cit14","unstructured":"Safety and efficacy study of romiplostim to treat ITP in pediatric subjects Ongoing study July 2007"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0015|cit15","unstructured":"P3 study to evaluate efficacy and safety of AMG 531 in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura Ongoing study October 2007"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0016|cit16","unstructured":"Efficacy and safety study of eltrombopag in pediatric patients with thrombocytopenia from chronic ITP (PETIT) Ongoing study September 2009"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008235.pub2-BIB0018|cit18","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2004-12-4598","article-title":"How I treat idiopathic thrombocytopenic purpura(ITP)","volume":"106","author":"Cines","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V85.2.391.391","article-title":"The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets","volume":"85","author":"Debili","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0026|cit26","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31(1)","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"abstract 2909","DOI":"10.1182\/blood.V104.11.2909.2909","article-title":"Species specificity and receptor domain interaction of a small molecule TPO receptor agonist","volume":"104","author":"Erickson-Miller","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Experimental Hematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0030|cit30","first-page":"87","article-title":"Idiopathic thrombocytopenic purpura: diagnosis and management","volume":"316","author":"George","year":"1998","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0037-1963(00)90116-1","article-title":"Treatment options for chronic idiopathic (immune) thrombocytopenic purpura","volume":"37","author":"George","year":"2000","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0032|cit32","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(96)12118-8","article-title":"Autoimmune (idiopathic) thrombocytopenic purpura","volume":"349","author":"Karpaktin","year":"1997","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008235.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0609.2007.00999.x","article-title":"New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura","volume":"80 (Suppl 69)","author":"Kuter","year":"2008","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0039|cit39","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1532\/IJH97.04168","article-title":"The effect of antiplatelet autoantibodies on megakaryocytopoiesis","volume":"91","author":"McMillan","year":"2005","journal-title":"International Journal of Hematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06339.x","article-title":"An open-label, unit dose-finding study of AMG 531 a novel, thrombopoiesis stimulating peptidbody, in patients with immune thrombocytopenic purpura","volume":"135","author":"Newland","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008235.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0049-3848(09)70011-8","article-title":"Novel approaches in management of immune thrombocytopenia","volume":"123","author":"Panzer","year":"2009","journal-title":"Thrombosis Research"},{"issue":"4","key":"10.1002\/14651858.CD008235.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy","volume":"120","author":"Provan","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0044|cit44","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0045|cit45","first-page":"726","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood.V92.1.4.413k38_4_10","article-title":"Role of c-Mpl in early hematopoiesis","volume":"92","author":"Solar","year":"1998","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-140-3-200402030-00012","article-title":"Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review","volume":"140","author":"Vesely","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008235.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clinical Pharmacology & Therapeutics"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008235.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T10:15:22Z","timestamp":1692785722000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008235.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,7,6]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008235.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,6]]}}}